The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.a

Bronchospasm - Wheezing - Asthma

Evidence base very low

Publications

Price KS, Castells MC

Taxol reactions.

Allergy and asthma proceedings. 2002;23(3):205-8

Cormio G, Di Vagno G, Melilli GA, Cazzolla A, Di Gesù G, Carriero C, Cramarossa D, Loverro G, Selvaggi L

Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.

Journal of chemotherapy (Florence, Italy). 1999;11(5):407-9

Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE

Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(6):2032-7

Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS

Phase I trial of taxol in patients with advanced cancer.

Cancer treatment reports. 1987;71(12):1171-7